Seeing Is Believing
RNAZ is currently covered by 1 analysts with an average price target of $23.91. This is a potential upside of $16.35 (216.27%) from yesterday's end of day stock price of $7.56.
Transcode Therapeutics's activity chart (see below) currently has 0 price targets and 10 ratings on display. The stock rating distribution of RNAZ is 100% BUY.
Analysts average stock forecasts to be materialized ratio is 85.71% with an average time for these price targets to be met of 109 days.
Highest price target for RNAZ is $20, Lowest price target is $20, average price target is $23.91.
Most recent stock forecast was given by EMILY BODNAR from HC WAINWRIGHT on 18-Dec-2024. First documented stock forecast 07-Jun-2022.
Currently out of the existing stock ratings of RNAZ, 8 are a BUY (100%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$20
$12.44 (164.55%)
$3
1 months 14 days ago
(18-Dec-2024)
6/7 (85.71%)
$16.35 (447.95%)
109
What is RNAZ (Transcode Therapeutics) average time for price targets to be met?
Which analyst has the current highest performing score on RNAZ (Transcode Therapeutics) with a proven track record?
Which analyst has the most public recommendations on RNAZ (Transcode Therapeutics)?
Which analyst is the currently most bullish on RNAZ (Transcode Therapeutics)?